Will AI be innovation or renovation for biopharma?
We have all been reading about the companies making headlines for their use of AI in biopharma. Real results from large investments in platforms, new partnerships that are changing the business model paradigm, and innovations in clinical trial management are starting to come in.

How will big pharma approach innovations? Is today’s biotech model really yesterday’s?

Have your say – how is your organization using AI, as innovation or renovation?* *
Submit
This form was created inside of MarketingPro Group. Report Abuse - Terms of Service